Search for a trial

Urethral suspension using vas deferens for prevention of urine incontinence after robot-assisted laparoscopic prostatectomy (RALP)

Improve postoperative urine continence after prostatectomy for prostate cancer.

A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATION THERAPY

The objective of the study is to evaluate the safety and efficacy of eculizumab to prevent AMR in sensitized recipients of living donor kidney transplants requiring desensitization therapy.

Remote ischemic preconditioning to reduce contrast-induced nephropathy.

To demonstrate that remote ischemic preconditioning reduces contrast-induced nephropathy in patients ar high-rish of CIN (according CBO guidelines) next to the use of pre- and posthydration.

Autologous BM derived MSCs in combination with everolimus to preserve renal structure and function in renal recipients

A 6-month study of efficacy and safety comparing concentration-controlled Certican® with MSCs to Certican® with standard tacrolimus in renal transplant recipients

Efficacy and safety of forced diuresis and guided fluid replacement
therapy on contrast media induced nephropathy; a feasibility study

2.1 Primary Objective: To evaluate the feasibility of RenalGuard for diuresis-guided fluid replacement therapy (ability to match in and output) (time to desired diuresis>200ml/hour) To evaluate the safety of forced diuresis and fluid…

A Randomized, Placebo-Controlled, Phase-2A, Pilot Study to Evaluate the Effects of a Multi-Species Probiotic Formulation on the Quality of Life of Female Recurrent Urinary Tract Infection Patients

Primary Objective: 1. To assess the impact of Winclove CLEAR on the quality of life of female rUTI patients.Secondary Objectives: 2. To assess the impact of Winclove CLEAR on the incidence of UTI and the (associated) urinary microbiota composition…

A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combination with mycophenolate mofetil (MMF) and corticosteroids (CS), with and without tacrolimus (Tac), in de novo renal transplant recipients

Primary:Part 1: PK, PD and SafetyTo assess the safety, tolerability and pharmacokinetics of multiple IV and SC doses of CFZ533 in combination with MMF, CS, and Tac (standard exposure) in de novo renal transplant patients over the treatment and…

EREctile Conservation after prostate radiation Therapy (ERECT);
a prospective phase 2 trial

Investigation of maintenance of erectile function after MR-guided radiotherapy with neurovascular sparing in patients with localized prostate cancer.

The effect of intradialytic supplementation in chronic hemodialysis patients; a pilot study

The primary objective of this pilot study is the feasibility of prolonged intra-dialytic creatine supplementation. The secondary objectives of this pilot study are to study the safety of prolonged intra-dialytic creatine supplementation for dialysis…

A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of Osocimab to ESRD patients on regular hemodialysis.

In this study researchers want to learn about the safety of drug Osocimab at low and high doses in adult participants with kidney disease undergoing regular dialysis. Patients with kidney disease undergoing regular dialysis are at high risk for…

A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients (CIRRUS I, CCFZ553A2201)

Primary Objective(s) (Cohort 1):* To demonstrate that CFZ533 600 mg and/or 300 mg bi-weekly (Q2W), subcutaneous (SC), is non-inferior to a tacrolimus-based regimen with respect to the proportion of patients who experience composite efficacy failure…

A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care control, in adult de novo liver transplant recipients with a 12-month additional follow-up and a long-term extension (CONTRAIL I).

This study will allow the assessment of the ability of CFZ533 to replace calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing potentially better renal function with an expected similar safety and tolerability profile.…